On August 5, Centene rose 5.06% in regular trading, trading at $67.335/share, with turnover of $149 million. The rally was driven by a wave of analyst upgrades following the company's significantly stronger-than-expected Q2 results.

On the catalyst front, Bernstein raised its price target on Centene from $68 to $79 on August 3, maintaining an Outperform rating. Previously, Barclays lifted its target from $75 to $80. The upgrades were prompted by Centene's Q2 adjusted EPS of $2.51, which dramatically exceeded the consensus estimate of $1.08. Revenue came in at $53.579 billion, well above the $47.617 billion estimate. The company also raised its full-year adjusted EPS guidance to above $4.80, significantly higher than the Street's $3.51 expectation.

RBC Capital noted that approximately $0.50 of Q2 adjusted EPS was driven by non-recurring settlement items and cautioned that Medicaid margin recovery may not meaningfully materialize until H2 2027. The company also lowered its Medicaid membership forecast to an 8%-9% year-over-year decline and announced a voluntary separation program expected to cost $315-$365 million in severance expenses.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)